Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Software Streamlines, Reduces Costs to Develop and Market Medical Device Technologies

By LabMedica International staff writers
Posted on 30 Apr 2009
Preliminary due diligence and fund development of new medical device technologies can cost up to US$75,000 and take up to three months. More...
But innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers, and others now have access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars, according to the software developer.

E-Zassi (Fernandina, FL, USA) Chief Executive Officer Peter M. von Dyck, remarked, "Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed, or commercialized." These critical details, according to Mr. von Dyck, include: a new technology's probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution, and sales burdens.

E-Zassi dot com is predictive decision-support software that provides rapid due diligence, triaging, and assessment of new medical device innovations. Members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases. Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants.

All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years. "We now know how this business and technology 'DNA' can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technologic opportunities," stated Mr. von Dyck. "Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time, and enhance success rates."

E-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions, a privately held company focused on innovation and development in medical devices.

Related Links:

e-Zassi



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.